FilingApr 21, 2026
Regulatory filing — Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against…▸
medium impact
ReadoutApr 21, 2026
Clinical data — Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting▸
medium impact
Data +Apr 08, 2026
Positive data — Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension▸
high impact
AdComMar 19, 2026
FDA advisory — Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review▸
high impact
AdComMar 05, 2026
FDA advisory — Tech Chips Lead Wall Street Rebound as Broadcom Crushes Estimates▸
high impact
AdComMar 04, 2026
FDA advisory — These Stocks Are Today’s Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and More▸
high impact
FilingFeb 28, 2026
Regulatory filing — Moderna’s EU Backing For Combo Vaccine Shifts Respiratory Growth Focus▸
medium impact
FilingFeb 27, 2026
Regulatory filing — European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketi…▸
medium impact
ApprovalFeb 25, 2026
FDA approval — FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market▸
high impact
EarningsFeb 13, 2026
FY 2025 report+17.7%positive
EarningsJan 12, 2026
FY 2025 report+16.3%positive
EarningsNov 06, 2025
Q3 2025 report+8.5%positive
EarningsAug 01, 2025
Q2 2025 report-3.2%negative
Data +Jul 10, 2025
mRNA-4157 Phase 3 interim (melanoma)▸
high impact
EarningsMay 01, 2025
Q1 2025 report-9.6%negative
EarningsFeb 14, 2025
FY 2024 report+2.2%muted
EarningsJan 13, 2025
FY 2024 report-4.0%negative
EarningsNov 07, 2024
Q3 2024 report-13.5%negative
Data +Sep 10, 2024
mRNA-4157 Phase 2b melanoma 3-year follow-up▸
high impact
EarningsAug 01, 2024
Q2 2024 report-12.6%negative
ApprovalMay 31, 2024
mRESVIA (RSV) FDA approval▸
high impact
EarningsMay 02, 2024
Q1 2024 report-3.6%negative